Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13D for Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (GLYC).
- Disclosed ownership: 20%.
- Date of event: 13 Jun 2025.
Fairmount Funds Management LLC - 13 Jun 2025 SCHEDULE 13D Report for Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (GLYC)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- GLYC
- Shares outstanding
- 15,628,914 shares
- Disclosed Ownership
- 3,124,220 shares
- Ownership
- 20%
- Form type
- SCHEDULE 13D
- Filing time
- 23 Jun 2025, 18:32:36 UTC
- Date of event
- 13 Jun 2025
- Next filing
- 08 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 20% ownership in Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (GLYC) on 13 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Jun 2025, 18:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 3,124,220 | 0 | 3,124,220 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II L.P. | 20% | 3,124,220 | 0 | 3,124,220 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001769651 |
| Peter Evan Harwin | 20% | 3,124,220 | 0 | 3,124,220 | /s/ Peter Harwin | Peter Harwin | 0001663607 |
| Tomas Kiselak | 20% | 3,124,220 | 0 | 3,124,220 | /s/ Tomas Kiselak | Tomas Kiselak | 0001830177 |